{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:52:03Z","timestamp":1793638323071,"version":"4.5.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s10038-020-00863-0","type":"journal-article","created":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T12:02:17Z","timestamp":1603627337000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis"],"prefix":"10.1038","volume":"66","author":[{"given":"Xinghao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-3440","authenticated-orcid":false,"given":"Ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"863_CR1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.1964.03070220062023","volume":"190","author":"D Berkowitz","year":"1964","unstructured":"Berkowitz D. Blood lipid and uric acid interrelationships. Jama. 1964;190:856\u20138.","journal-title":"Jama."},{"key":"863_CR2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/0026-0495(89)90110-8","volume":"38","author":"K Matsubara","year":"1989","unstructured":"Matsubara K, Matsuzawa Y, Jiao S, Takama T, Kubo M, Tarui S. Relationship between hypertriglyceridemia and uric acid production in primary gout. Metab Clin Exp. 1989;38:698\u2013701.","journal-title":"Metab Clin Exp."},{"key":"863_CR3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3346\/jkms.2005.20.6.1029","volume":"20","author":"YH Rho","year":"2005","unstructured":"Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20:1029\u201333.","journal-title":"J Korean Med Sci."},{"key":"863_CR4","first-page":"341","volume":"17","author":"HK Choi","year":"2005","unstructured":"Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol. 2005;17:341\u20135.","journal-title":"Curr Opin Rheumatol"},{"key":"863_CR5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","volume":"14","author":"RL Wortmann","year":"2002","unstructured":"Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281\u20136.","journal-title":"Curr Opin Rheumatol."},{"key":"863_CR6","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/clc.20511","volume":"33","author":"G Lippi","year":"2010","unstructured":"Lippi G, Montagnana M, Luca Salvagno G, Targher G, Cesare, Guidi G. Epidemiological association between uric acid concentration in plasma, lipoprotein (a), and the traditional lipid profile. Clin Cardiol. 2010;33:E76\u201380.","journal-title":"Clin Cardiol."},{"key":"863_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2008.05.022","volume":"202","author":"AC Gagliardi","year":"2009","unstructured":"Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11\u20137.","journal-title":"Atherosclerosis."},{"key":"863_CR8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.amjmed.2005.03.043","volume":"118","author":"JF Baker","year":"2005","unstructured":"Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816\u201326.","journal-title":"Am J Med"},{"key":"863_CR9","doi-asserted-by":"crossref","unstructured":"Peng T-C, Wang C-C, Kao T-W, Chan JY-H, Yang Y-H, Chang Y-W, et al. Relationship between hyperuricemia and lipid profiles in US adults. BioMed Res Int. 2015;2015:127596.","DOI":"10.1155\/2015\/127596"},{"key":"863_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Care Res Off J Am Coll Rheumatol. 2007;57:109\u201315.","journal-title":"Arthritis Care Res Off J Am Coll Rheumatol"},{"key":"863_CR11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1047-2797(97)00204-4","volume":"8","author":"W Rathmann","year":"1998","unstructured":"Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Ann Epidemiol. 1998;8:250\u201361.","journal-title":"Ann Epidemiol."},{"key":"863_CR12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/annrheumdis-2014-206191","volume":"75","author":"H Matsuo","year":"2016","unstructured":"Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis. 2016;75:652\u20139.","journal-title":"Ann Rheum Dis."},{"key":"863_CR13","volume":"8","author":"JY Jung","year":"2018","unstructured":"Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. Sci Rep. 2018;8:16767.","journal-title":"Sci Rep."},{"key":"863_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3904\/kjim.2006.21.2.89","volume":"21","author":"YH Lee","year":"2006","unstructured":"Lee YH, Lee CH, Lee J. Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med. 2006;21:89\u201393.","journal-title":"Korean J Intern Med."},{"key":"863_CR15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","volume":"42","author":"MD Feher","year":"2003","unstructured":"Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003;42:321\u20135.","journal-title":"Rheumatology."},{"key":"863_CR16","doi-asserted-by":"crossref","unstructured":"Tinahones F, Vazquez F, Soriguer F, Collantes E. Lipoproteins in patients with isolated hyperuricemia. In: Purine and pyrimidine metabolism in man IX. Springer; Adv Exp Med Biol. 1998. pp. 61\u20137.","DOI":"10.1007\/978-1-4615-5381-6_12"},{"key":"863_CR17","doi-asserted-by":"crossref","first-page":"e19088","DOI":"10.1097\/MD.0000000000019088","volume":"99","author":"S Chen","year":"2020","unstructured":"Chen S, Yang H, Chen Y, Wang J, Xu L, Miao M, et al. Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis. Medicine. 2020;99:e19088.","journal-title":"Medicine."},{"key":"863_CR18","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601.","journal-title":"BMJ"},{"key":"863_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"G Davey Smith","year":"2003","unstructured":"Davey Smith G, Ebrahim S. \u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1\u201322.","journal-title":"Int J Epidemiol"},{"key":"863_CR20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2009.812","volume":"301","author":"G Thanassoulis","year":"2009","unstructured":"Thanassoulis G, O\u2019Donnell CJ. Mendelian randomization: nature\u2019s randomized trial in the post-genome era. JAMA. 2009;301:2386\u20138.","journal-title":"JAMA."},{"key":"863_CR21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/hmg\/ddy384","volume":"28","author":"P Zeng","year":"2019","unstructured":"Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28:688\u201397.","journal-title":"Hum Mol Genet."},{"key":"863_CR22","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0602-x","volume":"14","author":"C Bonilla","year":"2016","unstructured":"Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, et al. Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med. 2016;14:66.","journal-title":"BMC Med."},{"key":"863_CR23","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","volume":"45","author":"CJ Willer","year":"2013","unstructured":"Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274\u201383.","journal-title":"Nat Genet"},{"key":"863_CR24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A K\u00f6ttgen","year":"2013","unstructured":"K\u00f6ttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145.","journal-title":"Nat Genet"},{"key":"863_CR25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fgene.2019.00618","volume":"10","author":"P Zeng","year":"2019","unstructured":"Zeng P, Zhou X. Causal association between birth weight and adult diseases: evidence from a Mendelian randomisation analysis. Front Genet. 2019;10:618.","journal-title":"Front Genet."},{"key":"863_CR26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375.","journal-title":"Am J Hum Genet."},{"key":"863_CR27","doi-asserted-by":"crossref","first-page":"e1002314","DOI":"10.1371\/journal.pmed.1002314","volume":"14","author":"AJ Noyce","year":"2017","unstructured":"Noyce AJ, Kia DA, Hemani G, Nicolas A, Price TR, De Pablo-Fernandez E, et al. Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study [e1002314]. Plos Med. 2017;14:e1002314.","journal-title":"Plos Med."},{"key":"863_CR28","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1177\/0962280215597579","volume":"26","author":"S Burgess","year":"2017","unstructured":"Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26:2333\u201355.","journal-title":"Stat Methods Med Res."},{"key":"863_CR29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Smith GD, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304\u201314.","journal-title":"Genet Epidemiol."},{"key":"863_CR30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658\u201365.","journal-title":"Genet Epidemiol."},{"key":"863_CR31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377\u201389.","journal-title":"Eur J Epidemiol."},{"key":"863_CR32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/ije\/dyz149","volume":"48","author":"RC Richmond","year":"2019","unstructured":"Richmond RC, Davey Smith G. Commentary: orienting causal relationships between two phenotypes using bidirectional Mendelian randomization. Int J Epidemiol. 2019;48:907\u201311.","journal-title":"Int J Epidemiol."},{"key":"863_CR33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/aje\/kwu283","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181:251\u201360.","journal-title":"Am J Epidemiol"},{"key":"863_CR34","first-page":"k2893","volume":"362","author":"Drug, Office TBE.","year":"2018","unstructured":"Drug, Office TBE. Latest guidance on the management of gout. BMJ. 2018;362:k2893.","journal-title":"BMJ."},{"key":"863_CR35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","volume":"37","author":"TJ VanderWeele","year":"2016","unstructured":"VanderWeele TJ. Mediation analysis: a practitioner\u2019s guide. Annu Rev Public Health. 2016;37:17\u201332.","journal-title":"Annu Rev Public Health."},{"key":"863_CR36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ije\/dyu176","volume":"44","author":"S Burgess","year":"2015","unstructured":"Burgess S, Daniel RM, Butterworth AS, Thompson SG, Consortium E-I. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol. 2015;44:484\u201395.","journal-title":"Int J Epidemiol."},{"key":"863_CR37","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/sim.6522","volume":"34","author":"MFD Greco","year":"2015","unstructured":"Greco MFD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34:2926\u201340.","journal-title":"Stat Med."},{"key":"863_CR38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/sim.650","volume":"20","author":"SE Brockwell","year":"2001","unstructured":"Brockwell SE, Gordon IR. A comparison of statistical methods for meta\u2010analysis. Stat Med. 2001;20:825\u201340.","journal-title":"Stat Med."},{"key":"863_CR39","doi-asserted-by":"crossref","unstructured":"Pascart T, Norberciak L, Ea HK, Guggenbuhl P, Liot\u00e9 F. Patients With Early-Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross-Sectional Epidemiologic Survey. Arthritis Care Res (Hoboken). 2019;71:986\u201392.","DOI":"10.1002\/acr.23706"},{"key":"863_CR40","doi-asserted-by":"crossref","unstructured":"Li X, Meng X, He Y, Spiliopoulou A, Timofeeva M, Wei W-Q, et al. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: a phenome-wide mendelian randomization study. PLoS Med. 2019;16:e1002937.","DOI":"10.1371\/journal.pmed.1002937"},{"key":"863_CR41","doi-asserted-by":"crossref","unstructured":"Karalis DG. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clinic Proceedings. 2009;84:345\u201352.","DOI":"10.4065\/84.4.345"},{"key":"863_CR42","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.2337\/diacare.26.11.3153","volume":"26","author":"C Lorenzo","year":"2003","unstructured":"Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26:3153\u20139.","journal-title":"Diabetes Care."},{"key":"863_CR43","volume":"7","author":"NAKZ Iwani","year":"2017","unstructured":"Iwani NAKZ, Jalaludin MY, Zin RMWM, Fuziah MZ, Hong JYH, Abqariyah Y, et al. Triglyceride to HDL-C ratio is associated with insulin resistance in overweight and obese children. Sci Rep. 2017;7:40055.","journal-title":"Sci Rep."},{"key":"863_CR44","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-017-0940-0","volume":"19","author":"C Vitali","year":"2017","unstructured":"Vitali C, Khetarpal SA, Rader DJ. HDL cholesterol metabolism and the risk of CHD: new insights from human genetics. Curr Cardiol Rep. 2017;19:132.","journal-title":"Curr Cardiol Rep."},{"key":"863_CR45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrcardio.2017.115","volume":"15","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Brewer HB Jr, Barter PJ, Bj\u00f6rkegren JL, Chapman MJ, Gaudet D, et al. HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nat Rev Cardiol. 2018;15:9.","journal-title":"Nat Rev Cardiol."},{"key":"863_CR46","first-page":"661","volume":"19","author":"N Giordano","year":"2001","unstructured":"Giordano N, Santacroce C, Mattii G, Geraci S, Amendola A, Gennari C. Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol. 2001;19:661\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"863_CR47","first-page":"25","volume":"78","author":"H Vuorinen-Markkola","year":"1994","unstructured":"Vuorinen-Markkola H, Yki-J\u00e4rvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"863_CR48","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"M-JA Brion","year":"2012","unstructured":"Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2012;42:1497\u2013501.","journal-title":"Int J Epidemiol"},{"key":"863_CR49","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.amjcard.2012.08.012","volume":"110","author":"T Keenan","year":"2012","unstructured":"Keenan T, Blaha MJ, Nasir K, Silverman MG, Tota-Maharaj R, Carvalho JA, et al. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol. 2012;110:1787\u201392.","journal-title":"Am J Cardiol."}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s10038-020-00863-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-020-00863-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-020-00863-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T04:19:58Z","timestamp":1635221998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s10038-020-00863-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1038\/s10038-020-00863-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-15933\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/19006296","asserted-by":"object"}]},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,25]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}